Sort
4,870 grants matching “glp 1”
Mouth barrier rinse of sustained-release poly(curcumin) to treat oral mucositis
$1,046,856Rohit Bhandari · Bluegrass Advanced Materials, Llc · R44 · FY2017 · DE
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
$1,045,564Charles Testa · Curza Inc · R01 · FY2021 · AI
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure
$1,044,010Lawrence Mahan · Madeleine Pharmaceuticals, Inc. · R44 · FY2021 · HL
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement
$1,042,983Jennifer E. Golden · University Of Tennessee Health Sci Ctr · U19 · FY2020 · AI
Pulmonary valved conduit xenograft with regeneration potential
$1,042,014Ajay Houde · Annoviant, Inc · R44 · FY2022 · HL
EARLY CLINICAL DEVELOPMENT OF MODIFIED P8 FOR THE TREATMENT OF ALZHEIMER'S DISEASE
$1,041,646Nazneen N Dewji · Cenna Biosciences, Inc. · R44 · FY2024 · AG
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH
$1,041,548Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2024 · DK
Regeneration of radiation-damaged salivary glands using neurogenicstimulation of stem cells
$1,039,386Chelsea Shields Bahney · Hydronovo, Inc · R44 · FY2025 · DE
INDâenabling development of MMâ008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring
$1,039,122Richard A Cone · Mucommune, Llc · R44 · FY2022 · HD
A novel immunotolerizing therapy for autoimmune vitiligo
$1,039,086Kanneganti Murthy · Radikal Therapeutics, Inc. · R44 · FY2017 · AR
National Center for Canine Models of Duchenne Muscular Dystrophy (NCDMD)
$1,038,570Joe N Kornegay · Univ Of North Carolina Chapel Hill · U24 · FY2009 · NS
National Center for Canine Models Muscular Dystrophy (NCDMD)
$1,038,570Joe N Kornegay · Univ Of North Carolina Chapel Hill · U24 · FY2009 · NS
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease
$1,037,264Jay Williams Hooper · Geneva Foundation · R01 · FY2017 · AI
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV
$1,037,049Richard A Cone · Mucommune, Llc · R44 · FY2024 · AI
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV
$1,036,484Richard A Cone · Mucommune, Llc · R44 · FY2023 · AI
SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps
$1,036,191John Nagi Kheir · Contech Medical, Inc. · R42 · FY2021 · HD
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis
$1,035,100Sharie Haugabook · National Center For Advancing Translational Sciences · ZIA · FY2018 · TR
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management
$1,031,733Bozena Korczak · Vascular Vision Pharmaceuticals Company · R44 · FY2024 · HL
Ambient light activatable opsin based therapy for age-related macular degeneration
$1,031,182Samarendra Kumar Mohanty · Nanoscope Technologies, Llc · R44 · FY2018 · EY
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management
$1,030,837Bozena Korczak · Vascular Vision Pharmaceuticals Company · R44 · FY2023 · HL
INDâenabling development of MMâ008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring
$1,028,445Richard A Cone · Mucommune, Llc · R44 · FY2023 · HD
Development of Novel Therapeutic Agents for Norovirus Infection
$1,027,980Kyeong-Ok Chang · Kansas State University · U01 · FY2010 · AI
Treatment of pulmonary fibrosis with inhibitors of integrin alphavbeta1.
$1,025,193Dean Sheppard · University Of California, San Francisco · UH2 · FY2015 · HL
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma
$1,025,001Margaret Kenny Offermann · Oncospherix, Inc. · R44 · FY2024 · CA
IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis
$1,025,000Keiichiro Kushiro · Mucommune, Llc · R44 · FY2025 · AI